Form 4 MannKind Corp: Michael A. Friedman (Director) For: 17 November
This article reports on a Form 4 filing for MannKind Corp, indicating that Michael A. Friedman, a director, was involved in a transaction on November 17. The filing provides details on insider trading activity for the company (MNKD).
State Street Reveals 4.7% Ownership Stake in MannKind Corporation
State Street Corporation has disclosed a 4.7% beneficial ownership stake in MannKind Corporation, as detailed in a Schedule 13G filing with the SEC. As of September 30, 2026, State Street holds 15,096,712 shares of MannKind common stock through five investment adviser subsidiaries. The filing indicates shared voting power over 14,316,800 shares and shared dispositive power over all 15,096,712 shares, with the acquisition made in the ordinary course of business.
MannKind to Participate in Upcoming Investor Conferences
MannKind Corporation announced that its CEO, Michael Castagna, and CFO, Chris Prentiss, will provide a business update at two investor conferences in London. They will participate in a fireside chat at the UBS Global Biopharma Conference and a presentation at the Jefferies Global Healthcare Conference. Live webcasts and replays of these presentations will be available on MannKind’s Investor Relations website.
Two London conferences will feature business updates from MannKind's CEO and CFO on Nov. 17 and 18.
MannKind (Nasdaq: MNKD) announced that its CEO, Michael Castagna, and CFO, Chris Prentiss, will provide business updates at two investor conferences in London on November 17 and 18, 2026. They will participate in a fireside chat at the UBS Global Biopharma Conference and deliver a presentation at the Jefferies Global Healthcare Conference. Live webcasts and replays of both events will be available on MannKind's Investor Relations website.
State Street reports 15.1 million MannKind (MNKD) shares, but no sole voting power.
State Street Corporation has reported a beneficial ownership of 15,096,712 shares, or a 4.7% stake, in MannKind Corp (MNKD) as of September 30, 2026. The filing indicates that State Street holds shared voting power over 14,316,800 shares and shared dispositive power over 15,096,712 shares, with no sole voting or dispositive power over any MannKind shares. This information was disclosed in a SCHEDULE 13G SEC filing.
MNKD 10-Q - MannKind Corporation sec form 10-q quarterly reports
This article from Quantisnow provides a real-time overview of MannKind Corporation's (MNKD) SEC Form 10-Q quarterly reports. It lists recent and historical 10-Q filings, indicating the number of days since each filing. The page also offers links to other MNKD SEC categories and information.
Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum
Cantor Fitzgerald has increased its price target for MannKind Corp. (NASDAQ:MNKD) shares to $10.00 from $8.00, maintaining an Overweight rating. This decision is driven by strong momentum for Tyvaso DPI and a delay in a competing product. The firm also anticipates future contributions from the Furoscix autoinjector and is watching MNKD-201, an inhaled nintedanib treatment, as an emerging asset, expecting better visibility into these programs' value in the coming quarters.
MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow Launch Exceeds Expectations
MannKind Corp (MNKD) reported a 24% year-over-year increase in Q3 2026 revenue, reaching $101.9 million, driven by strong performances from the FuroSix ReadyFlow launch and the pediatric Afrezza launch. The company anticipates a return to profitability in Q4 2026 and expects to be profitable on an annual basis in 2027. Despite a GAAP net loss for Q3 due to acquisition-related non-cash expenses, MannKind is focused on continued revenue growth and pipeline development, with several IPF candidates in progress.
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation reported strong financial results for the third quarter of 2026, with total revenues of $101.9 million, a 24% increase year-over-year. This growth was primarily driven by the successful launch and rapid adoption of Furoscix ReadyFlow and increased Afrezza prescriptions following its pediatric launch. The company also announced advancements in its pipeline, including positive Phase 1b results for nintedanib DPI and progress in its inhaled GLP-1 program.
MannKind’s IPF inhalation medical treatment passes Phase 1b
MannKind Corp., a biopharmaceutical company, announced positive results from its Phase 1b INFLO-1 clinical trial for nintedanib dry powder inhalation, an investigational treatment for idiopathic pulmonary fibrosis (IPF). The inhaled medicine aims to deliver the drug directly to the lungs, reducing systemic exposure and minimizing severe gastrointestinal side effects associated with the oral form. The company is now enrolling patients for its global Phase 2 INFLO-2 study to further evaluate safety and efficacy.
MannKind's Furosix Ramp And Pediatric Afrezza Uptake Face First Real Test After Catalyst Sweep
MannKind faces a critical third-quarter earnings report as it shifts from launch preparation to execution after a year of significant spending. The company needs to demonstrate that its recent approvals, including pediatric Afrezza and the Furosix ReadyFlow auto-injector, are translating into revenue growth to justify the investment. Key areas of focus will be the Furosix sales ramp and the conversion of pediatric Afrezza scripts from cash programs to paid coverage.
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MannKind Corporation announced it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026. The management team will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss results and provide a business update. A live webcast and replay of the call will be available on the company's Investor Relations website.
MannKind Corporation (MNKD) Interactive Stock Chart - Yahoo Finance
This page provides an interactive stock chart for MannKind Corporation (MNKD) on Yahoo Finance, displaying its real-time price and after-hours trading activity. It also includes a list of recent news articles related to MannKind, detailing financial results, strategic developments, and clinical data presentations. The content highlights the company's stock performance and key corporate announcements.
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MannKind Corporation announced it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026. The management team will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a business update, with a live webcast available on their Investor Relations website. MannKind is a biopharmaceutical company focused on innovative solutions for chronic cardiometabolic and orphan lung diseases.
Did Clinical Data On Furoscix ReadyFlow Just Shift MannKind (MNKD) Investment Narrative?
MannKind Corporation recently released clinical data on Furoscix ReadyFlow, demonstrating its IV equivalent performance for heart failure and chronic kidney disease patients. This data, highlighting the 10-second autoinjector's bioequivalence to IV furosemide, could significantly influence MannKind's product strategy and market demand. Investors are now focused on how this new data will impact the company's investment narrative, particularly concerning its potential for outpatient fluid management and a cleaner gross margin profile.
MannKind Corporation Estimates – NASDAQ:MNKD
This page provides financial estimates for MannKind Corporation (NASDAQ: MNKD), allowing users to explore reported financial data and analyst estimates across various statements and metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time, covering income statements, balance sheets, and cash flow data on both annual and quarterly bases.
Chardan starts coverage of MannKind stock with a USD 10.00 target
Chardan has initiated coverage of MannKind (MNKD) stock with a Buy rating and a USD 10.00 price target. This comes after MannKind reported second-quarter 2026 revenue of USD 109.37 million, exceeding the USD 108.92 million consensus. The article details MannKind's current trading prices, market capitalization, and recent corporate events.
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Chardan Capital analyst Andreas Argyrides initiated coverage on MannKind Corp (NASDAQ: MNKD) with a Buy rating and a price target of $10. This article summarizes top analyst initiations for Monday, October 19, 2026, highlighting several companies including Rush Street Interactive, newcleo plc, Hadron Energy Inc, and AIB Data Centers Inc.
Chardan initiates MannKind stock coverage with buy rating on pipeline
Chardan has initiated coverage of MannKind Corp. (NASDAQ:MNKD) with a buy rating and a $10.00 price target, citing the company's strong pipeline and shifting revenue mix. The investment thesis is based on Furoscix, Afrezza’s pediatric expansion, and inhaled nintedanib (MNKD-201). This positive outlook aligns with broader analyst sentiment, which forecasts profitability for MannKind this year.
MannKind Corporation (MNKD) Stock Price, News, Quote & History
This article provides comprehensive financial information for MannKind Corporation (MNKD), including its stock price, historical data, key performance indicators, and recent news. It highlights the company's biopharmaceutical focus, commercial products like Afrezza and Furoscix, and pipeline treatments for chronic diseases. The data shows MNKD's stock performance, analyst insights, and financial statistics as of October 15, 2026.
MannKind to Participate in the Chardan Healthcare Conference
MannKind Corporation announced that its CEO, Michael Castagna, will participate in a panel discussion at the Chardan Healthcare Conference on October 20, 2026. The panel will focus on innovation in chronic respiratory diseases, and management will also hold one-on-one meetings with investors. MannKind is a biopharmaceutical company specializing in patient-centric solutions for cardiometabolic and orphan lung diseases.
MannKind to Participate in the Chardan Healthcare Conference
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference. The panel will take place on October 20, 2026, and a live webcast will be available on MannKind's Investor Relations website. Management will also hold one-on-one meetings with investors during the event.
MannKind Corporation Share Price - MNKD, RNS News, Articles, Quotes, & Charts (NASDAQ:MNKD)
This page provides an overview of MannKind Corporation (NASDAQ: MNKD), including its current stock price, market capitalization, and a brief description of its focus on therapeutic products for diabetes and pulmonary arterial hypertension. It also lists historical news and events related to the company, such as milestone payments and FDA approvals for its inhaled insulin product, Afrezza. The site also includes links to news articles and market data for the company.
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026
MannKind Corporation announced new clinical data at the HFSA 2026 meeting for its Furoscix ReadyFlow autoinjector, showing it delivers IV-equivalent diuresis across various injection sites. The autoinjector, approved by the FDA in July 2026, provides a rapid and effective outpatient treatment for fluid overload in heart failure and chronic kidney disease patients. These findings highlight the product's potential to enhance patient management by offering flexible and consistent therapeutic performance outside of traditional hospital settings.
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.
MannKind announced new clinical data for its Furoscix ReadyFlow autoinjector, showing comparable urine output and total drug exposure to intravenous furosemide for treating fluid overload in heart failure and chronic kidney disease patients. The device delivers an 80 mg/mL dose in under 10 seconds, reinforcing its potential for outpatient management. The findings, presented at HFSA 2026, also confirmed consistent pharmacokinetic and pharmacodynamic profiles across different injection sites (thigh and upper arm).
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
MannKind Corporation announced new clinical data for Furoscix ReadyFlow, an autoinjector delivering furosemide for edema management in heart failure and chronic kidney disease patients. The data, presented at HFSA 2026, reinforces its IV-equivalent exposure and diuretic effect, supporting its use in outpatient settings. Findings highlight consistent pharmacokinetic and pharmacodynamic profiles across different injection sites and comparable efficacy to the Furoscix On-body Infusor.
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute
A recent Delaware court ruling found Liquidia's Yutrepia infringes on United Therapeutics' patent, a decision expected to positively impact MannKind Corp (MNKD) due to increased royalty income from Tyvaso DPI. Truist maintained a Buy rating on MNKD with a $6 price target, citing strengthened prospects. Despite potential undervaluation based on its Price-to-Sales ratio and a GF Value™ of $7.53, MNKD exhibits mixed fundamentals with strong growth and momentum but weak financial strength and ongoing unprofitability, leading to cautious investor sentiment.
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal
MannKind Corporation's stock (MNKD) rose over 11% due to a new licensing deal with Rose Pharma for a GLP-1 weight management drug using MannKind's Technosphere platform. The agreement grants MannKind equity, royalties, and a board seat, with Rose Pharma funding later-stage development. This asset-light model provides MannKind with leveraged upside in the growing obesity and IBS pain markets while limiting its financial risk.
Steven Binder sells $128,477 of MannKind (MNKD) stock
Steven Binder, a director at MannKind Corp (MNKD), recently sold 39,051 shares of common stock for $128,477, executed under a Rule 10b5-1 trading plan established in December 2025. Following the sale, Binder retains 713,258 shares. The company has also seen positive developments including FDA approvals, product launches, and favorable analyst ratings, despite Binder's stock sale.
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK
Director Steven Binder sold 39,051 shares of MannKind Corp (MNKD) on September 25, 2026, adding to a pattern of insider selling over the past year. Despite the stock trading at a significant discount to its GF Value, categorized as a "Possible Value Trap," the consistent insider selling and mixed guru ownership trends suggest caution for investors. MannKind Corp is a biopharmaceutical company known for its inhaled therapeutic products like Afrezza.
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com
Steven B. Binder, a director at MannKind Corp (NASDAQ:MNKD), sold 39,051 shares of the company's common stock for $128,477 on September 25, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Binder directly holds 713,258 shares. The stock, currently trading at $3.35, is down 49% from its 52-week high but has surged nearly 47% in the past six months, with InvestingPro analysis suggesting it is undervalued.
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com
Steven Binder, a director at MannKind Corp (NASDAQ:MNKD), sold 39,051 shares of common stock for $128,477 on September 25, 2026, through a pre-established trading plan. Following the sale, Binder directly holds 713,258 shares. The company recently reported strong Q2 revenue and received FDA approvals, with analysts maintaining positive ratings.
Form 4 MannKind Corp For: 28 September By Investing.com
This article announces the filing of Form 4 for MannKind Corp (MNKD) pertaining to September 28. It is a brief report from Investing.com, providing information on an insider trading disclosure without further details within the article itself. The publication time is listed as September 29, 2026, at 01:50 UTC.
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder.
MannKind Corporation director Steven Binder has filed a notice to sell 39,051 common shares, valued at $128,477.79, with an approximate sale date of September 25, 2026. The shares were acquired through performance stock units on July 15, 2026. The filing also details three prior 10b5-1 sales by Binder in July, August, and September 2026, totaling significant gross proceeds.
MannKind Corporation (MNKD) Options Chain - Yahoo Finance
This article provides the options chain data for MannKind Corporation (MNKD) on Yahoo Finance. It displays real-time stock prices, after-hours trading information, and detailed options data including strike prices, last trade dates, bid/ask prices, and implied volatility for both calls and puts. However, the options chain currently shows no available calls or puts.
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind (NASDAQ: MNKD) is experiencing strong early demand for its newly launched FUROSCIX ReadyFlow autoinjector, with physician interest expanding beyond previous prescribers. The company's pediatric Afrezza launch is also gaining momentum, targeting a concentrated network of endocrinologists with a bridge program to aid patient access. Additionally, MannKind's MNKD-201, a treatment for idiopathic pulmonary fibrosis (IPF), is progressing towards Phase 2, showing promising tolerability in earlier trials.
MannKind director Steven Binder sells $127,855 in company stock
MannKind director Steven Binder sold 33,558 shares of the company's common stock for $127,855 on September 10, 2026, as part of a pre-established trading plan. Following the sale, Binder still directly holds 752,309 shares. Despite a recent dip, MannKind's stock is up 35% over six months and is considered undervalued by InvestingPro analysis, with recent positive news including FDA approvals and strong Q2 revenue.
MannKind director Steven Binder sells $127,855 in company stock By Investing.com
Steven B. Binder, a director at MannKind Corp. (NASDAQ:MNKD), sold 33,558 shares of company stock for $127,855 on September 10, 2026, as part of a pre-established trading plan. This transaction leaves him with 752,309 shares, while the stock is currently trading at $3.75, which InvestingPro analysis suggests is undervalued with a fair value of $4.04. The sale follows MannKind's strong second-quarter revenue, FDA approvals for new products, and positive analyst ratings.
Cantor Fitzgerald reiterates Overweight rating on MannKind stock
Cantor Fitzgerald has reiterated its Overweight rating and an $8.00 price target for MannKind Corporation (NASDAQ: MNKD), citing the company's strong opportunity in idiopathic pulmonary fibrosis (IPF) with three programs underway. Despite unprofitability in the past year, analysts predict MannKind will achieve profitability this year. The company has also seen recent successes with positive Phase 1b data for inhaled nintedanib, FDA approval for the Furoscix autoinjector, and exceeding Q2 revenue expectations.
A rapid-acting, short-duration inhaled treatment is being developed for weight management
MannKind and Rose Pharma Inc. have entered a licensing and collaboration agreement to develop ROSE-010 Technosphere, an inhaled, rapid-acting, short-duration GLP-1 for weight management. MannKind will license its Technosphere platform to Rose Pharma and provide development support through Phase 1b, receiving equity, royalties, and a board seat in return. ROSE-010, also showing potential for irritable bowel syndrome, aims to offer a flexible and patient-controlled approach to weight management.
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind Corporation shares are trading lower after announcing a licensing and collaboration agreement with Rose Pharma. The partnership focuses on developing an inhaled, rapid-acting GLP-1 receptor agonist for weight management, combining Rose Pharma's molecule with MannKind's Technosphere inhalation technology. MannKind will receive an equity interest and potential royalties, supporting the development through Phase 1b.
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan
MannKind director Steven Binder has filed a Rule 144 notice to sell up to 33,558 shares of MannKind common stock, valued at $132,218.52, which are related to restricted stock units acquired on July 15, 2026. This planned sale follows earlier Rule 10b5-1 plan sales by Binder in July and August 2026. The filing indicates a neutral impact and sentiment on the company's stock.
MannKind to Present at Upcoming Investor Conferences
MannKind Corporation announced that its management team will present at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts and recorded versions of these presentations will be available on MannKind's investor relations website. The company specializes in biopharmaceutical solutions for chronic cardiometabolic and orphan lung diseases.
MannKind to Present at Upcoming Investor Conferences
MannKind Corporation (Nasdaq: MNKD) announced its management team will present at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts and recorded versions of these presentations will be available on the company's investor relations website. MannKind is a biopharmaceutical company focused on innovative solutions for chronic cardiometabolic and orphan lung diseases.
MannKind to Present at Upcoming Investor Conferences
MannKind Corporation announced that its management team will present at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts of these presentations will be available on MannKind's investor relations website, with recorded versions accessible for 90 days afterward. MannKind is a biopharmaceutical company focusing on cardiometabolic and orphan lung diseases.
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
MannKind (MNKD) stock is considered 48% undervalued with a fair value estimated at $7.59 per share, significantly higher than its recent $3.95 close. This valuation is based on the projected growth of Afrezza through international expansion and a broadened salesforce, coupled with the progress of its late-stage pipeline programs for respiratory diseases. Despite recent underperformance, the company's future revenue growth and potential for expanded product offerings support the undervalued narrative, though risks like Afrezza's limited market adoption persist.
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering
MannKind Corporation (NASDAQ: MNKD) has submitted a prospectus supplement to its automatic shelf registration statement, which includes a legal opinion from Cooley LLP validating the legality of its common stock issuance and sale. This filing was made with the SEC on August 21, 2026, and confirms that MannKind's common stock is traded on NASDAQ. The report also clarifies that MannKind does not qualify as an emerging growth company.
MannKind files legal opinion for common stock offering under shelf registration
MannKind (MNKD) has filed a prospectus supplement and submitted a legal opinion from Cooley LLP regarding the issuance and sale of common stock under its existing automatic shelf registration on Form S-3. This action facilitates the company's ability to offer and sell common stock in the future. The legal opinion is attached as Exhibit 5.1 to a Current Report on Form 8-K.
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares
MannKind Corporation (NASDAQ: MNKD) has registered for resale up to 12.85 million shares of common stock by existing selling stockholders. This includes 10.44 million issued shares and 2.41 million shares issuable upon the exercise of pre-funded warrants from a July 24, 2026 private placement, where common shares were sold at $3.89 and pre-funded warrants at $3.88 with a $0.01 exercise price. MannKind will not receive proceeds from this resale but will cover registration expenses, and the selling stockholders may use various methods for disposal.
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story
MannKind Corporation recently reported rising second-quarter 2026 revenue to US$109.37 million, but also a shift from profit to a net loss of US$19.03 million. This return to losses, despite higher revenue, highlights pressure from the company's cost base. The article suggests that while the Technosphere platform and programs like Afrezza and INFLO 1 data for nintedanib DPI offer potential, increasing R&D and commercial costs remain a significant risk to future profitability.